<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>22040645</identifier>
<setSpec>1989-7286</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Castro-Rebollo, M</dc:author>
<dc:author>Montes-Mollón, M A</dc:author>
<dc:author>Teus, M A</dc:author>
<dc:author>Pérez-Rico, C</dc:author>
<dc:description xml:lang="en">CASE REPORT A 75-year-old man with bilateral idiopathic lipid keratopathy underwent a penetrating keratoplasty in the left eye. One month later, there was deep corneal neovascularisation extending across the bed and the graft-host interface, with a whitish opacity surrounding the vessels. Topical bevacizumab (25mg/mL) was administered 4 times daily for 2 months with partial regression of corneal neovascularization. DISCUSSION Topical bevacizumab may be useful in preventing a recurrence of lipid deposition after penetrating keratoplasty in patients with bilateral primary lipid keratopathy, although its long-term efficacy needs to be assessed.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>2011 Nov </dc:date>
<dc:title xml:lang="es">Eficacia de bevacizumab tópico en queratopatía lipoidea bilateral primaria.</dc:title>
<dc:title xml:lang="en">[Effectiveness of topical bevacizumab in bilateral primary lipid keratopathy].</dc:title>
<dc:publisher>Archivos de la Sociedad Espanola de Oftalmologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
